Norinco offers 8x8 SPAAG
China North Industries Corporation (Norinco) is promoting a new 35mm self-propelled antiaircraft gun (SPAAG) on the international market. The vehicle was shown in model form at Eurosatory 2016.
Labelled SWS2, the armoured air defence vehicle is based on the well-known VN1 8x8 chassis with a front-mounted engine and a new compact turret. The SWS2 features a single-barrel 35mm revolver cannon and four TY-90-based surface-to-air missiles (SAM).
These missiles are also used on the Yi-Tian, an air defence system based on the WMZ551 6x6 chassis, and which Norinco first offered for export in 2005. The TY-90 missile has a maximum
Already have an account? Log in
Want to keep reading this article?
More from Land Warfare
-
DSEI 2025: OpenWorks launches new system for on-the-move targeting
Vision Pace uses OpenWorks’ artificial intelligence (AI) classifiers and trackers to detect, track and identify multiple targets in land and naval applications for air defence.
-
DSEI 2025: Patria’s FAMOUS becomes TRACKX with production ready before end of 2027
The first two Technology Test Beds (TTBs) have been completed and put through a series of company trials including sand, snow, swamp, forest and tarmac.
-
DSEI 2025: General Dynamics firms up Ajax for potential British Army IFV requirement
Following the cancellation of the Lockheed Martin UK Warrior Capability Sustainment Programme (WCSP), the British Army will have a serious capability gap when the current Warrior infantry fighting vehicle (IFV) is soon phased out of service.
-
DSEI 2025: Trials completed for new version of Tridon air defence gun
Less than two years ago, Sweden’s BAE Systems Bofors announced it was developing a new 40mm short-range air defence system using internal research and development funding, calling it the Tridon Mk2.
-
DSEI 2025: Rheinmetall adds Lockheed Martin missile punch to Fuchs vehicle
The combination of the Rheinmetall platform with Lockheed Martin missiles is seen as the bringing together of mature systems to provide a capability in the medium term, but trials could be as long as 12 months away.